<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN">
<html lang="en">
	<head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
		<meta name="viewport" content="width=device-width, initial-scale=1">
		<title></title>
		<link rel="stylesheet" href="css/ka.css" type="text/css">
		<link rel="stylesheet" href="css/animate.css" type="text/css">
		<script type="text/javascript" src="js/base.js">
</script>
		<script type="text/javascript" src="js/Common.js">
</script>
		<script type="text/javascript" charset="utf-8">

		var ANIMATION = [
			/*
		stagger(flip('.box'), '.subtext'),
			['#legend', '#chart1'],
			['.bar'],
			['.number', '#lines']
		*/
		];

		</script>
	</head>
	<body class="slide-14">
		<div id="main">
			<div id="content">
				<div class="whiteoverlay"></div>
				<div id="logo">
					<img src="images/blkAbbott_logo.png" width="154" height="52" alt="Abbott">
				</div>
				<h1>
					Most common moderate/severe related<br>
					adverse events and grade 2/3/4 lab abnormalities<sup>4</sup>
				</h1>
				<div id="leftchart" onclick="makecall('PopupMessageHTML',Array('ka-14-chart-01','Baseline Chart 1','450','365','0','0','830','570'));"></div>
				<div class="smallcap">
					<div>
						AST: aspartate aminotransferase:CrCL: cleatinine clearance: ULN: Upper limit of normal.
					</div>
					<div>
						<span class="symbol">*</span>Includes all events occuring in at least 2% of subjects in either group.
					</div>
					<div>
						<span class="symbol">†</span> The <em>P</em> value based on Fisher exact text.
					</div>
					<div>
						<span class="symbol">‡</span> Adverse events of hypertryceridemia represent a subset of TG elevations requiring medical intervention or deemed significant per investigator to warrant an adverse event report.
					</div>
				</div>
				<div id="rightcol">
					<div class="blk_bullet">
						The most common adverse reaction was diarrhea, which was generally of mild to moderate severity. Diarrhea of any severity during 48 weeks of KALETRA therapy was 60% in the QD group vs 57% in the BID group.
					</div>
					<div class="blk_bullet">
						More patients receiving KALETRA tablets QD (14, 4.2%) had ongoing diarrhea at the time of discontinuation vs patients receiving KALETRA tablets BID (6, 1.8%).
					</div>
				</div>
				<div class="btns">
					<div class="studybtn">
						<a href="#"><img src="images/Button-StudyDesignA.png" width="132" height="42" alt="Study Design" onclick="makecall('PopupMessageHTMLWithTopnav',Array('ka-07-popup-03','&lt;DIV align=\'left\'&gt;&lt;font color=\'white\' face=\'Helvetica\'&gt;&lt;p &gt;&lt;strong&gt;}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}Study Design&lt;sup&gt;4,5&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/font&gt;&lt;/DIV&gt;','780','670','10','0','530','460'));"></a>
					</div>
					<div class="baselinebtn">
						<a href="#"><img src="images/Button-Baseline_A.png" width="132" height="42" alt="Baseline Values" onclick="makecall('PopupMessageHTMLWithTopnav',Array('ka-07-popup-02','&lt;DIV align=\'left\'&gt;&lt;font color=\'white\' face=\'Helvetica\'&gt;&lt;p &gt;&lt;strong&gt;}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}}Baseline Values&lt;sup&gt;4&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/font&gt;&lt;/DIV&gt;','920','670','10','0','605','565'));"></a>
					</div>
				</div>
				<div id="footer">
					<p>
						Please click buttons above for indication<br>
						and Important Safety Information about KALETRA.
					</p>
				</div>
			</div>
		</div>
	</body>
</html>
